Loading company…
Beijing-based genomic testing company offering whole-genome and whole-exome sequencing for disease risk assessment.
Founded in 2016 in Beijing, China, Mega Genomics provides genomic testing that assesses risk for hereditary cancers, recessive genetic disorders and complex diseases. Its packages include whole-genome testing and whole-exome sequencing for adults and children, sold directly to consumers. Zhe Xiao is CEO. In June 2022, the company completed an IPO raising HKD 215.28 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in